Hoping for a better ending

28/11/24 -"The Q3 exceeded our expectations and we foresee increased momentum from new capacity in 2024, despite the economic situation. However, our projections for 2025 have been revised downward, primarily ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

28/11/24

Download

You may also be interested by these reports :

21/01/26

Wacker Chemie

We have lowered our EPS estimates for FY25/FY26 to -€0.91/€0.45, from €1.15/€3.57, reflecting weaker sales expectations (FY25/FY26: €5.5bn/€5.6bn vs ...

14/01/26

BRAIN Biotech AG

Cost discipline helps, but delivery still falls short

04/12/25

Idea Kicker

We last highlighted Umicore (Reduce, Belgium) in November 2021, when the stock began to fall from its all-time high of €60.0. Since then, the share ...

25/11/25

LANXESS

The EPS change for 2025 reflects our more conservative opinion of EBITDA (discussed in DCF section) and earnings from investment accounted using ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

Arkema